Reported
Lowest–highest estimate
The chart could not be loaded. Try again or view the figures below.
| Value | YoY | Lowest–highest | Analysts | |
|---|---|---|---|---|
Innate Pharma SA
PAR:IPH
Innate Pharma SA
PAR:IPH
Price:
1.302
EUR
2.84%
Market Closed
Market Cap:
€145.4m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Innate Pharma SA
PAR:IPH
|
FR |
|
Regis Corp
F:RGI0
|
US |
|
Kelso Technologies Inc
F:LB4A
|
CA |
|
D
|
Donnelley Financial Solutions Inc
F:1DN
|
US |
|
Braemar Shipping Services PLC
LSE:BMS
|
UK |
|
Feintool International Holding AG
F:FTO
|
CH |
|
S
|
SEB SA
XMUN:GRB
|
FR |
|
F
|
FirstGroup PLC
F:FGR
|
UK |
|
S
|
Sub Sri Thai Real Estate Investment Trust
SET:SSTRT
|
TH |
|
C
|
Cracker Barrel Old Country Store Inc
XMUN:OLD
|
US |
|
E
|
Eco&Dream Co Ltd
KOSDAQ:101360
|
KR |
Wall St Price Targets
IPH Price Forecast
Based on 4 analysts
Based on 4 analysts
+394% Upside
from
€1.302
today
Innate Pharma SA (IPH)’s 12-month stock price forecast through October 2027 has a consensus target of €6.426, implying 394% upside. The forecast is based on price targets from 4 Wall Street analysts.
IPH Analyst Rating
No ratings yet
No ratings yet
Innate Pharma SA Competitors:
Price Targets
Price Targets
Why do you have more estimates than other sites?
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is IPH's stock price target?
Price Target
6.426
EUR
6.426
EUR
According to Wall Street analysts, the average 1-year price target for IPH is 6.426 EUR with a low forecast of 5.656 EUR and a high forecast of 8.4 EUR.
What is the Revenue forecast for Innate Pharma SA?
Projected CAGR
92%
92%
Over the last 13 years, the compound annual growth rate for Revenue has been -10%. The projected CAGR for the next 7 years is 92%.
What is the Gross Profit forecast for Innate Pharma SA?
Projected CAGR
994%
994%
Over the last 13 years, the compound annual growth rate for Gross Profit has been -22%. The projected CAGR for the next 3 years is 994%.